BACKGROUND: Screening, brief intervention, and referral to treatment may reduce substance misuse but has received minimal study among women who are treated in reproductive health settings. OBJECTIVE: The purpose of this study was to determine whether "screening, brief intervention and referral to treatment" that is delivered either electronically or by clinician are more effective than enhanced usual care in decreasing days of primary substance use. STUDY DESIGN: Women from 2 reproductive centers who smoked cigarettes or misused alcohol, illicit drugs, or prescription medication were allocated randomly to "screening, brief intervention and referral to treatment" delivered electronically or by clinician or to enhanced usual care. Assessments were completed at baseline and at 1-, 3-, and 6-months after a baseline has been established. Coprimary outcomes were days/ months of primary substance use and postintervention treatment use. A sample size of 660 women was planned; randomization was stratified by primary substance use and pregnancy status. "Screening, brief intervention and referral to treatment" groups were compared with enhanced usual care groups with the use of generalized estimation equations, and effect sizes were calculated with the use of Cohen's d. RESULTS: Between September 2011 and January 2015, women were assigned randomly to a group: 143 women (16.8% pregnant) in the electronic-delivered "screening, brief intervention and referral to treatment" group, 145 women (18.6% pregnant) in the clinician-delivered "screening, brief intervention and referral to treatment" group, and 151 women (19.2% pregnant) in the enhanced usual care group; the retention was >84%. Based on the generalized estimating equations model, predicted mean days per month of use at baseline for primary substance were 23.9 days (95% confidence interval, 22.4e25.5) for the electronicdelivered group, 22.8 days (95% confidence interval, 21.4e24.3) for the clinician-delivered group, and 23.5 days (95% confidence interval, 22.2, 24.9) for enhanced usual care, which respectively declined to 20. [8] [9] [10] ; however, some recent reports indicate that SBIRT can be used successfully to reduce noninjection drug use in medical settings. 11, 12 The American Congress of Obstetricians and Gynecologists recommends substance use screening and referral to assist women who can benefit from treatment. 13 Establishing efficacy in this group is critical because it includes women who are pregnant or contemplating pregnancy and who have special concerns.
W omen are at highest risk of the development of a substance use disorder during their reproductive years (18e44); yet, 85% of those who need care for substance misuse neither receive it nor believe they need it. 1 Screening, brief intervention, and referral to treatment (SBIRT) is a proactive technique that identifies individuals who likely misuse substances and provides a brief intervention that enhances their motivation to reduce or stop substance misuse and to seek treatment. 2 SBIRT is efficacious for the reduction of unhealthy alcohol 3, 4 and tobacco use [5] [6] [7] and less well-established for decreasing illicit drug use or increasing treatment engagement [8] [9] [10] ; however, some recent reports indicate that SBIRT can be used successfully to reduce noninjection drug use in medical settings. 11, 12 The American Congress of Obstetricians and Gynecologists recommends substance use screening and referral to assist women who can benefit from treatment. 13 Establishing efficacy in this group is critical because it includes women who are pregnant or contemplating pregnancy and who have special concerns. 13 The brevity of SBIRT has increased its reach in many medical settings, and its proactive approach is critical for reaching the nontreatment-seeking majority. 14 However, requisite training and time commitment still constitute implementation barriers. 15 Electronic administration of SBIRT (e-SBIRT) can reduce time commitment and training needs and can enhance SBIRT's reliable delivery. Several randomized trials support the acceptability and efficacy of e-SBIRT for postpartum substance misuse. 16, 17 One trial showed equivalence between electronic-and counselor-delivered brief interventions for reduction in drug use among general medical patients in a primary care setting, although there was no control condition. 18, 19 The purpose of this study was to test the efficacy of SBIRT, based on motivational principles 2 and delivered as a single session either electronically via a 
Materials and Methods
This study was a randomized controlled trial that allocated women to 3 groups: e-SBIRT, clinician-delivered SBIRT (SBIRT), or an educational pamphlet plus existing treatment resources that constituted EUC (the control condition). Data collection occurred between September 5, 2011, and January 28, 2015. The study was approved by an institutional review board and included a certificate of confidentiality from the National Institutes of Health. The trial is registered at ClinicalTrials.gov, NCT01539525.
Women in 2 urban academic hospitalbased reproductive healthcare clinics were voluntarily screened for cigarette smoking or misuse of alcohol, illicit drugs, or prescription medication. Screening took place during usually scheduled reproductive health visits and was conducted by research assistants who used an audio-enabled, computerassisted self-interview tool. Women were informed about the study before screening. Eligible participants were nonpregnant and pregnant women who were at least 18 years old and who scored positive on the World Health Organization substance use screener: the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). 20 Substancespecific scores on the ASSIST range from 0e33; a brief intervention is recommended for scores between 4 and 26 for all substances other than alcohol, for which the range is 11e26. 20 According to the ASSIST guidelines, for all substances other than alcohol, the cutoff for inclusion in this study was a score of !4, which indicates use weekly or more in past 3 months or less frequent use with consequences; for alcohol, our cutoff was !11 for nonpregnant women and !6 for pregnant women. Exclusions were (1) current or imminent incarceration or hospitalization; (2) inability to provide contact information for 2 persons; (3) participation in substance use treatment or self-help programs in the past 3 months; (4) or inability to interview and consent in English. All participants provided written informed consent and received compensation in gift cards for completion of study assessments ($40 at baseline, $50, $60, and $100 for the respective 1-, 3-, and 6-month follow-up assessments).
Participants were assigned randomly to treatment condition with the use of urn randomization, 21 balancing on primary substance (nicotine/alcohol/marijuana/drug) and pregnancy (pregnant/ not pregnant). An individual's response to SBIRT may vary with different primary substance use, [3] [4] [5] [6] [7] [8] [9] and many women substantially decrease or stop substance use in pregnancy, 22 potentially confounding treatment effects if treatment groups were not balanced on these variables. We used the gRand urn randomization program (version 1.1; Yale University, New Haven, CT) that runs in Microsoft Access (Microsoft Corporation, Redmond, WA). Research staff ran the program from a laptop computer to assign participants to condition after the baseline assessment to decrease bias. Although most follow-up assessments were completed by a different research staff person from the one who originally assigned condition, this was not always logistically possible; therefore, blinding was not guaranteed in the study.
All participants received a handout that listed local treatment and self-help services. Both single-session, 20-minute SBIRTs were based on motivational interviewing (MI), an evidenced-based, patient-centered, brief therapeutic approach that helps patients resolve ambivalence toward positive behavioral change. 23 The e-SBIRT (described in detail elsewhere 24 ) featured an interactive, 3-dimensional, mobile narrator that delivered the intervention. The goal was to support the importance of, and a woman's confidence in, cutting down or quitting substances and obtaining treatment. The approximately 20-minute SBIRT incorporated the same MI components provided in e-SBIRT, except that the clinicians had discretion in delivering them. Two study nurses, 3 social workers, and 1 obstetriciangynecologist received a 15-hour SBIRT workshop training followed by practice cases with feedback and coaching and monthly group supervision during the trial, all of which was provided by the primary author (S.M.) per current standards. 23 Afterward, a sample of audio recorded SBIRT sessions were rated with the Independent Tape Rater Scale 25 to ensure the treatment was delivered as designed (with fidelity). EUC involved a 2-minute interaction in which patients were informed about their level of substance use risk as derived from the ASSIST and told about local treatments listed on the handout that could help them cut down or stop their use.
Assessments were completed at baseline and at 1-, 3-and 6-months after randomization with the use of an audio-enabled, computer-assisted selfinterview to collect demographics, ASSIST scores, participant-identified primary substance, substance use diagnoses from the Mini-International Neuropsychiatric Inventory (version 5.0.0; University of South Florida College of Medicine, Tampa, FL), 26 the Fagerstrom Test for Nicotine Dependence, 27 and post-SBIRT substance use treatment and self-help information (eg, Alcoholics Anonymous) from the Treatment Utilization Form. 28 Timeline Followback interviews 29 were delivered via trained research staff who used calendar-based recall methods to collect information on substances used during the previous 28 days.
Although the Timeline Followback interview provided daily data on substance use, we also collected urine samples at each assessment. The short window of detection (a few days) for urine toxicology tests renders this a suboptimal outcome for the many weeks between assessments, but testing enhances the veracity of self-report. 30 Samples were tested for physiologic temperature to reduce risk of tampering and were analyzed by Redwood Toxicology Labs (Santa Rosa, CA) for drugs (amphetamines, barbiturates, benzodiazepines, buprenorphine, cocaine, methadone, methaqualone, opiates, oxycodone, phencyclidine, ajog.org
propoxyphene, cannabinoids), alcohol (ethylglucuronide/ethylsulfate), and nicotine (cotinine) using an enzyme immunoassay procedure. False-negative rates per urine analysis were low and similar across conditions and assessment points, which supports the equivalent veracity of self-reports among randomized groups and mitigating concerns about unblinded data collection (Supplementary Table 1) .
We prespecified coprimary outcomes: (1) self-reported days of primary substance use per month (28 days) and (2) treatment utilization (substance use treatment and self-help programs), both assessed at 1-, 3-, and 6-months after randomization. We created 7 nonoverlapping time intervals (baseline and months 1e6) from the Timeline Followback interviews that were collected at each assessment point. Missing data were collected at subsequent assessments when possible. Intervals with <14 days were coded as missing (0.1% of possible data points); intervals of 14e27 days were extrapolated to 28 days (1.6% of possible data points). Treatment use during follow-up assessments was based on self-report, but, with the exception of self-help programs, were verified with treatment providers. We also reviewed medical records for use of medication indicative of treatment (eg, nicotine replacement therapy). Only verified reports were used in the analyses.
Using the 3-group design, a significance threshold of 2-sided probability values of <.05, an effect size of .28, and expected 10% loss to follow up, an a priori power analysis resulted in a target sample size of 660. A 25% reduction in funding support led to a reduced final sample size. Power analysis was conducted with PS Power (Vanderbilt University, Nashville, TN). 31 The reduced sample size did not alter study methods or planned analyses.
We examined between-group differences in days/month of primary substance use over time using generalized estimating equations (GEE) to allow for analysis of auto-correlated, count outcome variables. We specified a negative binomial distribution to account for over-dispersion (ie, variance > mean) in the days/month of primary substance use, a log link function, and a first-order autoregressive working correlation structure. We estimated b coefficients using quasi-likelihood estimation methods, and sandwich/empiric standard errors were calculated. Explanatory variables in the GEE model included treatment group (0¼EUC, 1¼e-SBIRT, 2¼SBIRT), time, and treatment group by time interaction. We modeled time as a continuous variable for months 0e6 and included linear and quadratic effects of time to test for a curvilinear relationship between substance use and time (ie, that the effects of a brief intervention like SBIRT would attenuate over time). The primary effect of interest was the treatment group by time interaction. Multiple logistic regression analyses were performed to examine differences in treatment use between treatment groups, adjusted for the same stratifying variables. Holm's step-down multiple testing procedure was applied to control the type 1 error rate. All analyses were intention-to-treat and conducted with the use of SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC).
Results
We approached 2421 women for screening and randomly assigned 439 (e-SBIRT,143 [ Figure 1 ). Retention rates exceeded 84% at all follow-up points and were comparable among groups. The 3 intervention groups were similar demographically (Table 1) : most were nonHispanic, African American (66.7%), nonpregnant (81.8%) women in their early 30s, not living with a spouse or partner (55.1%), and not working (66.3%). Most had graduated high school or some form of post-secondary education (66.6%). The mean ASSIST score of 22.5 (SD¼8.1) for the primary substance indicated a moderate risk. Substance use rates were similar among intervention groups. At baseline, women reported using their primary substance 23.7AE7.9 days in the past month. Among pregnant women, days of past-month primary substance use were 23.1AE8.3 days (raw data; Table 1 ). Most participants met diagnostic criteria for nicotine use disorder (56.4%); 33.7%, 27.7%, and 20.2% of the participants met criteria for cannabis, alcohol, or another illicit drug use disorder, respectively. Diagnoses for the pregnant subset were 50.6%, 38.0%, 13.9%, and 10.1% for nicotine, cannabis, alcohol, or another illicit drug use disorder, respectively.
Of those women who were assigned randomly, 436 (99%) received the intervention on the same day as the baseline assessment. Three women did not show for the intervention after randomization. Six women were enrolled in error after baseline (1 reported no substance use the previous month, and 5 disclosed substance use treatment during the 3-month period preceding baseline assessment). Independent fidelity ratings with 50% of the SBIRT sessions showed clinicians demonstrated adequate-to-very-good levels of MI performance (data available on request).
The GEE model included pregnant and nonpregnant women (Table 2) . Independent of pregnancy status, treatment group by linear and quadratic time interactions were significant for both e-SBIRT and SBIRT, even after application of the Holm's procedure to adjust for 2 comparisons. These interactions were due to initially steeper declines in days/month of use followed by an earlier leveling off for the women who received either form of SBIRT vs EUC (Figure 2 Participant flow in the trial of electronic-and clinician-delivered clinician delivered "screening, brief intervention, and referral to treatment" Original Research GYNECOLOGY ajog.org Figure 2 . Three-way interactions between treatment, time, and pregnancy status did not differ significantly in the effect of treatment over time between pregnant and nonpregnant women, although our study was not powered to test this difference. Overall, 121women (27.6%) used substance use treatment or self-help programs after SBIRT across follow-up points. Approximately one-half of the services that they sought were for smoking cessation (Table 3 ). Statistical models (Table 4) did not reveal differences in usage between groups. To better understand whether the severity of risk for substance-related problems moderated use, we conducted 2 sensitivity analyses. The first model adjusted for ASSIST score, and the second model included only women with an ASSIST score of !27 (which indicated a need for more intensive intervention beyond a brief intervention). No differences in odds of treatment use by treatment group were found in these additional models (Supplementary Tables 4 and 5 ).
Comment
In this investigation of women in reproductive health settings, both e-SBIRT and SBIRT significantly reduced days of primary substance use over the follow-up period compared with EUC.
There was no interaction for pregnancy status, which indicated that the response was similar for pregnant and nonpregnant women. At 3 months, substance use was reduced by 4 days in the usual care group, 7 days in the e-SBIRT group, and 6.3 days in the SBIRT group; differences were attenuated at 6 months. Exploratory analyses bolstered the strength of the primary outcome by showing that all substance use decreased at a higher rate in the SBIRT groups compared with EUC. These encouraging results are counterbalanced by the lack of difference in treatment-seeking among groups. Recent studies that examined the efficacy of SBIRT for drug use in mixed However, other work shows that younger women who receive services in inpatient medical settings 32 and emergency departments 33 benefit more from SBIRT than men. Women in their reproductive years may be uniquely receptive to SBIRT because substance use places their health and the well-being of their children or pregnancy at risk. 2 Our study included women who were largely in their early 30s, 18% of whom were pregnant. Participants were seeking reproductive healthcare services and may have recognized adverse consequences caused by their substance use in this context. A reduction of even a few days per month of substance use is likely to reduce some of these risks (eg, decreasing drinking during pregnancy can improve pregnancy outcomes). 34, 35 Although the study was not designed to compare 2 SBIRTmodalities, the mode in which SBIRT was delivered did not appear to influence outcomes. The comparative effectiveness of these 2 SBIRTs requires further evaluation. However, previous work that used a different intervention developed with the same e-SBIRT platform performed as well as an in-person brief intervention for drug misuse at 3-and 12-month followup assessments 18, 19 ; however, these trials did not include a control condition. In contrast, other trials with this platform, which used interventions more similar to that used in the present study, significantly decreased illicit drug use among postpartum women 16 and smoking during pregnancy. 36 The interactive nature of the program, use of tailored content based on respondents' motivational levels, and feedback about issues salient to women (eg, effects of substance use on children) may have contributed to e-SBIRT being on par with SBIRT. The potential benefits of increasing access to SBIRT via electronic delivery (eg, reliability, reduced staffing needs, easier implementation) are well documented, 17 and it may be more cost-effective.
Past studies show that brief advice and MI-based counseling are efficacious for dependent smokers, [5] [6] [7] particularly when combined with pharmacologic treatment. 37 Most women in our study (57.2%) reported nicotine as their primary substance. However, both SBIRT delivery platforms allowed for targeting other problematic substance use by tailoring content to the participant's preferred focus. This "all comers" approach makes sense from an implementation perspective in that 1 SBIRTapplication may be used to help women with a variety of different substance use problems. 38 Neither SBIRT method influenced treatment use, even after adjustment for baseline risk severity for primary substance use. About one-quarter of participants accessed professional treatment or self-help programs during the followup period; one-half of this usage was for smoking cessation purposes. This finding is consistent with low levels of treatment-seeking generally 1 and with the fact that women in this cohort were not being seen for substance use treatment. Moreover, other than nicotine dependence, most women did not meet criteria for a substance use disorder, and those who reported nonnicotine primary substance generally had moderate, rather than severe, risk, wherein a brief intervention without referral to treatment may be sufficient.
2 Perhaps a goal of decreasing nicotine or other substance use on their own was sufficient for these individuals who may have seen specialty treatment as unnecessary or inappropriate. Similarly, it is possible that the need to choose a treatment provider, to make an appointment, and to find transportation simply presents too great This study has numerous strengths: (1) a large group of women with a variety of substances misused, (2) inclusion of pregnant and nonpregnant women, (3) similarly formatted brief MI-based interventions to isolate potential differences in SBIRT delivery method, (4) independent verification of MI fidelity in SBIRT, (5) biochemical corroboration of primary substance use, (6) verified treatment use, and (7) high follow-up rates. The study also has limitations. It was conducted within urban academic healthcare settings primarily with nonHispanic African American participants, thereby limiting the findings' generalizability. In addition, study personnel who had been trained according to best practices and who were supervised monthly provided SBIRT. Hence, the magnitude of the effect of SBIRT when used by reproductive healthcare providers and staff remains to be determined. Finally, recruitment goals were decreased, although the power appears adequate given the significant condition differences.
In sum, a 20-minute SBIRT reduced days of primary substance use compared with EUC among women who sought reproductive health services. This finding supports the American Congress of Obstetricians and Gynecologists' opinion that the use of SBIRT can reduce or stop the use of substances that risk harm to women's health and the health of their children. Increasing access to SBIRT via electronic delivery may be a cost-effective and practical approach for the implementation of this intervention in busy reproductive healthcare centers. n a Cut-off scores for urine screens were cotinine (200 ng/mL), alcohol (0.04 gm/mL), amphetamines (500 ng/mL), cocaine (300 ng/mL), methamphetamines (1000 ng/mL), opiates (300 ng/mL), benzodiazepines (200 ng/mL), and THC (50 ng/mL). False-negative rates were determined by the number of participants who reported no use when they had a positive urine test result divided by the total number of positive urine test results for that substance. EUC, enhanced usual care; e-SBIRT, electronically delivered screening, brief intervention and referral to treatment; SBIRT, clinician delivered screening, brief intervention, and referral to treatment.
a Includes cocaine, opiates, PCP, benzodiazepine, and sleeping pills. 
SUPPLEMENTARY TABLE 5
Results of logistic regression model that predicts treatment use among a subset of women with an ASSIST score ‡27 (n[155) 
